GI Oncology Group Honored for Outstanding Patient Care

By Robin Hindery, UCSF Today | July 1, 2009

Members of UCSF's Gastrointestinal (GI) Oncology group are the inaugural recipients of the Helen Diller Family Quality Award, an honor that recognizes exceptional commitment to providing superior patient care.

The group, led by gastrointestinal cancer expert Alan Venook, MD, was named the top performer in the UCSF Helen Diller Family Comprehensive Cancer Center's quality initiative, a pilot project launched in 2007.

The quality initiative was created "to ensure patients are getting great, consistent care," and also to compare UCSF's performance in cancer care with other medical institutions, said Peter Carroll, MD, MPH, director of strategic planning and clinical services at the cancer center and chair of the UCSF Department of Urology.

Each practice within the cancer center at Mount Zion was asked to identify a significant quality metric for a specific cancer diagnosis, and then to submit a report summarizing the practice's performance based on that metric for fiscal year 2008.

An independent panel comprising Joshua Adler, MD, UCSF Medical Center's chief medical officer, Robert Hiatt, MD, PhD, the cancer center's deputy director, and Brigid Ide, RN, director of quality services for the medical center, rated the submissions.

The GI Oncology group ranked highest among the 20 practices that participated in the quality initiative. Five practices - Breast Oncology, Breast Surgery, Colorectal Surgery, Endocrine Surgery and GI Surgical Oncology - were named runners-up.

For its part, the GI Oncology group chose to monitor its compliance with the recommendation that colon cancer patients receive postoperative chemotherapy within nine months of diagnosis - a quality indicator endorsed by the National Comprehensive Cancer Network and the National Initiative for Cancer Care Quality.

Studies have demonstrated an 8 percent survival advantage among colon cancer patients who receive chemotherapy after surgery, said Ann Griffin, PhD, manager of the UCSF Cancer Registry.

Colon and rectal cancer will kill nearly 50,000 Americans in 2009, the National Cancer Institute estimates.

According to the GI Oncology group's practice report, among a random sample of 32 patients with stage 3 colon cancer who were diagnosed or treated at UCSF in 2007, each one received, or was recommended to receive, chemotherapy within nine months of surgery.

What's more, a review of UCSF cases submitted to the National Cancer Data Base from 1998 to 2006 showed that compliance with the postoperative chemotherapy guideline was consistently greater than 95 percent, Griffin said.

When compared with cancer programs at 259 teaching hospitals across the country, the five-year survival rate of UCSF's stage 3 colon cancer patients was significantly higher: 70 percent of UCSF patients were alive at five years after diagnosis, compared with 51 percent of patients at the other hospitals, Griffin said.

"We try to do our best, and I'm glad the metrics suggest we're doing that," said Venook, a professor of clinical medicine in the UCSF Division of Hematology/Oncology and the former associate chief of medical oncology.

Venook took the lead on the quality initiative, but three other members of the Division of Hematology/Oncology shared in the Helen Diller Family Quality Award: Andrew Ko, MD, assistant clinical professor; Michael Korn, MD, associate professor; and Emily Bergsland, MD, associate professor.



Read more at Robin Hindery, UCSF Today